Parkinsonism clinical trials at UCSF

1 research study open to eligible people

Parkinsonism is a condition that causes movement problems like shaking and stiffness. UCSF is conducting a study to see if a medicine called zoledronic acid can help prevent bone fractures in people with Parkinsonism. This study is home-based and involves a single infusion of the medicine.

Showing trials for

  • Parkinson's And Zoledronic Acid

    open to eligible people ages 60 years and up

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    San Francisco, California and other locations

Our lead scientists for Parkinsonism research studies include .

Last updated: